Longevity & AgingMetformin Cuts Delirium Risk by 14% Compared to Common Diabetes Drugs
A large multinational cohort study of over 860,000 type 2 diabetes patients found that metformin use was associated with a 14% lower risk of delirium and a 24% lower risk of all-cause mortality compared to DPP-4 inhibitors. Using propensity score matching to balance 84,221 pairs of patients, researchers confirmed these benefits held across age groups, sexes, and glycemic control levels. The findings reinforce metformin's status as the preferred first-line diabetes therapy, particularly for older patients or those vulnerable to neurocognitive decline. This study adds meaningful evidence that metformin's benefits may extend well beyond blood sugar control into neuroprotection and longevity.
